AstraZeneca flop a fresh blow to cancer immunotherapy combination – Reuters
Reuters |
AstraZeneca flop a fresh blow to cancer immunotherapy combination
Reuters The concept of combining two immunotherapy drugs to fight lung cancer – not so long ago one of the hottest ideas in cancer research – has suffered a fresh blow from the failure of an AstraZeneca (AZN.L) clinical study. AstraZeneca flop a fresh blow to cancer immunotherapy combination AstraZeneca flop a fresh blow to cancer immunotherapy … – KDAL AZ's immunotherapy combo fails again in lung cancer |
